| Exclusion Criteria: | 1) Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
2) Have received > 2 previous systemic treatment regimens for metastatic soft tissue sarcoma. For purposes of eligibility, neoadjuvant chemotherapy is not counted toward determining the number of prior systemic treatment regimens.
3) Patients with primary bone sarcoma (e.g., osteosarcoma, Ewing's sarcoma, chondrosarcoma), gastrointestinal stromal tumor (GIST), and Kaposi's sarcoma.
4) Patients with documented central nervous system or leptomeningeal metastasis (brain metastasis) at the time of study entry. Patients with signs or symptoms of neurological compromise should have appropriate radiographic imaging performed prior to study entry to rule out occult brain metastasis.
5) Patients with serious concomitant disorders, including active bacterial, fungal, or viral infection, incompatible with the study (at the discretion of the investigator).
6) Patients with a second primary malignancy that could affect compliance with the protocol or interpretation of the results. NOTE: Patients with adequately treated carcinoma of the skin (excluding melanoma) and patients with a prior history of malignancy who have been disease-free for more than 2 years are eligible.
7) Patients with serious preexisting medical conditions (at the investigator's discretion).
8) Patients receiving warfarin (Coumadin ®) therapy.
9) Persons who have previously completed or withdrawn from this study or any other study investigating LY573636.
10) Women who are pregnant or lactating.
11) Patients with a serum albumin < 3.3 g/dL (33 g/L) at time of study entry. |